Find, compare & contact
Comtess (Entacapone) API Manufacturers & Suppliers

Looking for Entacapone API 130929-57-6?

Description:

Here you will find a list of producers, manufacturers and distributors of Entacapone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Entacapone 

Synonyms:

Comtan , Comtess , Entacapona , Entacapone , Entacaponum  

Cas Number:

130929-57-6 

DrugBank number:

DB00494 

Unique Ingredient Identifier:

4975G9NM6T

Entacapone is a type of COMT inhibitors

COMT inhibitors, which stand for Catechol-O-methyltransferase inhibitors, are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various medical conditions. These inhibitors specifically target the enzyme catechol-O-methyltransferase, which plays a crucial role in the breakdown of certain neurotransmitters, such as dopamine, epinephrine, and norepinephrine.

The primary purpose of COMT inhibitors is to inhibit the activity of the COMT enzyme, thereby increasing the levels of these neurotransmitters in the brain and other parts of the body. By doing so, these inhibitors offer potential therapeutic benefits in the management of several disorders, including Parkinson's disease, psychiatric disorders, and pain syndromes.

The use of COMT inhibitors in the treatment of Parkinson's disease is particularly significant. These inhibitors, often used in combination with other medications like levodopa, help improve motor symptoms such as tremors, muscle rigidity, and bradykinesia. By prolonging the effects of levodopa, COMT inhibitors can enhance the therapeutic response and extend the "on" time for patients, reducing the fluctuations in motor control.

Furthermore, COMT inhibitors have shown promise in the field of psychiatry. By modulating the levels of neurotransmitters like dopamine, COMT inhibitors can help alleviate symptoms associated with mental health conditions, such as depression and schizophrenia. These inhibitors have also been explored for their potential analgesic effects in pain management, offering an alternative option for patients who do not respond well to conventional therapies.

In conclusion, COMT inhibitors are a vital subcategory of pharmaceutical APIs with significant therapeutic potential. Their ability to modulate neurotransmitter levels makes them valuable in the treatment of Parkinson's disease, psychiatric disorders, and pain syndromes. Ongoing research and development in this field aim to further enhance the efficacy and safety profile of these inhibitors, expanding their application in various medical domains.

Entacapone (COMT inhibitors), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Standard C&P from Taiwan, product country of origin Taiwan
• Signa from Mexico, product country of origin Mexico
• USV from India, product country of origin India
• HEC Pharm from Germany, product country of origin Germany
• Suryakala Laboratories Pvt Ltd from India, product country of origin India
• Fermion from Finland, product country of origin Finland
• Sun Pharma from India, product country of origin India
• Divis Labs. from India, product country of origin India
• Piramal Healthcare from United Kingdom, product country of origin India
• Hetero Labs from India, product country of origin India
• Piramal Pharma Solutions from India, product country of origin Unknown
• Erregierre from Italy, product country of origin Italy
• Moehs from Spain, product country of origin Spain

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.